{"id":726753,"date":"2023-01-30T08:18:09","date_gmt":"2023-01-30T13:18:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/"},"modified":"2023-01-30T08:18:09","modified_gmt":"2023-01-30T13:18:09","slug":"effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/","title":{"rendered":"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan.  30, 2023  (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, announced that the Company will present and host 1&#215;1 meetings at the 2023 BIO CEO &amp; Investor Conference from February 6-9, 2023 in New York City, NY.<\/p>\n<p>Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will provide an overview of the Company\u2019s clinical development pipeline and corporate strategy. The presentation will be given in-person at the New York Marriott Marquis on Monday, February 6th at 2:15 PM ET.<\/p>\n<p>Interested participants may register to access eFFECTOR Therapeutics\u2019 presentation and the entire conference on the BIO CEO &amp; Investor Conference event website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OMJGVZj-jcFmeTAhEXQbXh2dIbJ_InhQWTw_blGf_SVK6HNTNTUgqXGuFZ-Vnbi3TsLz6_hyuwVw5mIKw14TPEw5bc-Bz-WywDaM2Y_eglFXoWtUPB_XWooWddEO6reJjf0cEp2HwSknkFWZmLU1BZsNTxT0c-2DAnfhDgQE_dYNvLbQJwXG7F8T_84NeroX\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.bio.org\/events\/bio-ceo-investor-conference<\/a>.<\/p>\n<p>\n        <strong>About eFFECTOR Therapeutics<\/strong>\n      <\/p>\n<p>eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR\u2019s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR\u2019s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR\u2019s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR\u2019s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company\u2019s oncology focus, zotatifin is being evaluated as a potential host-directed antiviral therapy in patients with mild to moderate COVID-19 in collaboration with UCSF, which holds a $5 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:33%;width:33%;min-width:33%;vertical-align: top\">\n            <strong>Investors:<\/strong>\n          <\/td>\n<td style=\"max-width:33%;width:33%;min-width:33%;vertical-align: top\">\u00a0<\/td>\n<td style=\"max-width:34%;width:34%;min-width:34%;vertical-align: top\">\n            <strong>Media:<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Christopher M. Calabrese <br \/>Managing Director <br \/>LifeSci Advisors<br \/>917-680-5608<br \/><a href=\"mailto:ccalabrese@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">ccalabrese@lifesciadvisors.com<\/a><\/p>\n<\/td>\n<td style=\"vertical-align: top\">Kevin Gardner<br \/>Managing Director<br \/>LifeSci Advisors<br \/>617-283-2856<br \/><a href=\"mailto:kgardner@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/td>\n<td style=\"vertical-align: top\">Heidi Chokeir, Ph.D.<br \/>Managing Director<br \/>Evoke Canale<br \/>619-203-5391<br \/><a href=\"mailto:Heidi.chokeir@evokegroup.com\" rel=\"nofollow noopener\" target=\"_blank\">Heidi.chokeir@evokegroup.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MDMyOGRkYjctM2Y5Mi00YjZhLWE4MDgtMzczZTBhYjcyYzk4LTEwOTQwODI=\/tiny\/eFFECTOR-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, announced that the Company will present and host 1&#215;1 meetings at the 2023 BIO CEO &amp; Investor Conference from February 6-9, 2023 in New York City, NY. Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will provide an overview of the Company\u2019s clinical development pipeline and corporate strategy. The presentation will be given in-person at the New York Marriott Marquis on Monday, February 6th at 2:15 PM ET. Interested participants may register to access eFFECTOR Therapeutics\u2019 presentation and the entire conference on the BIO &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-726753","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, announced that the Company will present and host 1&#215;1 meetings at the 2023 BIO CEO &amp; Investor Conference from February 6-9, 2023 in New York City, NY. Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will provide an overview of the Company\u2019s clinical development pipeline and corporate strategy. The presentation will be given in-person at the New York Marriott Marquis on Monday, February 6th at 2:15 PM ET. Interested participants may register to access eFFECTOR Therapeutics\u2019 presentation and the entire conference on the BIO &hellip; Continue reading &quot;eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-30T13:18:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference\",\"datePublished\":\"2023-01-30T13:18:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/\"},\"wordCount\":429,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/\",\"name\":\"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=\",\"datePublished\":\"2023-01-30T13:18:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference - Market Newsdesk","og_description":"SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, announced that the Company will present and host 1&#215;1 meetings at the 2023 BIO CEO &amp; Investor Conference from February 6-9, 2023 in New York City, NY. Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will provide an overview of the Company\u2019s clinical development pipeline and corporate strategy. The presentation will be given in-person at the New York Marriott Marquis on Monday, February 6th at 2:15 PM ET. Interested participants may register to access eFFECTOR Therapeutics\u2019 presentation and the entire conference on the BIO &hellip; Continue reading \"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-30T13:18:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference","datePublished":"2023-01-30T13:18:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/"},"wordCount":429,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/","name":"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=","datePublished":"2023-01-30T13:18:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczODQ5NSM1Mzc5OTQxIzIwODI1MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-present-at-2023-bio-ceo-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"eFFECTOR Therapeutics to Present at 2023 BIO CEO &amp; Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=726753"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726753\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=726753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=726753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=726753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}